Cyberattack & Weak 2026 Outlook Weigh on BSX: Is the Stock a Sell?

Boston Scientific disclosed a cyberattack alongside weaker 2026 guidance, adding material uncertainty to its outlook. Combined with reported business pressures, the update raises investor concerns about near-term execution and whether risk should be reduced. The mix of cybersecurity disruption and guidance deterioration is likely to weigh on shares in the 1–3% range as markets reassess the stock’s forward trajectory.